NCT02302508 (PANDDA) is a Phase 4 clinical trial of Clopidogrel, Prasugrel, Ticagrelor in Diabetes, sponsored by Centre hospitalier de l'Université de Montréal (CHUM).

Who is sponsoring NCT02302508?

NCT02302508 is sponsored by Centre hospitalier de l'Université de Montréal (CHUM).

What drugs are being tested in NCT02302508?

Interventions in NCT02302508: Clopidogrel, Prasugrel, Ticagrelor.

Is NCT02302508 still recruiting?

NCT02302508 is currently withdrawn. Last updated 22 July 2019.

Last reviewed 2019-07-22 · How we verify

NCT02302508: PANDDA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PANDDA Study: Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients

Withdrawn Phase 4 Last updated 22 July 2019

What this trial tests

Phase 4 trial testing Clopidogrel, Prasugrel, Ticagrelor in Diabetes. Withdrawn.

Timeline

1 September 2019

Primary endpoint
1 December 2020

1 December 2021

Quick facts

Lead sponsor	Centre hospitalier de l'Université de Montréal (CHUM)
Phase	Phase 4
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	basic science
Start date	1 September 2019
Primary completion	1 December 2020
Estimated completion	1 December 2021
Sites	1 location across Canada

Drugs / interventions tested

Clopidogrel, Prasugrel, Ticagrelor — full drug profile →

Conditions studied

Diabetes — all drugs for Diabetes →

Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Who can join

Adults 18 to 80, any sex, with Diabetes. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Pharmacokinetics (AUC0-t metabolites and parent drug) of clopidogrel, prasugrel and ticagrelor.
Time frame: 30 days
The association between the T2D effects on antiplatelet drug's PK (AUC0-t metabolites, AUC0-t of parent drug) will be assessed after a single oral loading dose in patients with different diabetic status.

Sponsor's own description

Clopidogrel efficacy appears diminished in patients with type 2 diabetes (T2D) who continue to show an increased risk of adverse cardiovascular events and mortality compared to those without T2D.The aim of the first project is to describe the pharmacokinetic (PK) profile of three antiplatelet drugs in 4 groups of patients according to their diabetic or non-diabetic status. To this end, PK profiles will be determined after a single oral dose of 300 mg clopidogrel, 60 mg prasugrel and 180 mg ticagrelor in patients (n=108); 1) with T2D and good glycemic control; 2) with T2D and poor glycemic control; 3) with insulin-treated diabetes; and 4) non-diabetic subjects.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Other Centre hospitalier de l'Université de Montréal (CHUM) trials

Trials by the same sponsor.

NCT06735638 — Outside the Cage (OTC) Robotic Esophagectomy · Phase 1 · not yet recruiting
NCT07533253 — Rescue Distal Thrombectomy in Treatment for Persistent Distal Occlusions · NA · not yet recruiting
NCT05225272 — Effectiveness of an Enhanced Recovery After Surgery Protocol in Patients Undergoing On-pump Cardiac Surgery · not yet recruiting
NCT07497061 — Comparison of Two Surgical Techniques for the Treatment of Trigger Fingers: Longitudinal Opening Versus Complete A1 Pull · NA · not yet recruiting
NCT07196410 — KAN-004 for Immune-Related Diarrhea or Colitis · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02302508 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre hospitalier de l'Université de Montréal (CHUM)
Last refreshed: 22 July 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02302508.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing